Dirithromycin
- Generic Name
- Dirithromycin
- Drug Type
- Small Molecule
- Chemical Formula
- C42H78N2O14
- CAS Number
- 62013-04-1
- Unique Ingredient Identifier
- 1801D76STL
- Background
Dirithromycin is a macrolide glycopeptide antibiotic used to treat many different types of bacterial infections, such as bronchitis, pneumonia, tonsillitis, and even skin infections.
- Indication
For the treatment of the following mild-to-moderate infections caused by susceptible strains of microorganisms: acute bacterial exacerbations of chronic bronchitis, secondary bacterial infection of acute bronchitis, community-acquired pneumonia, pharyngitis/tonsilitis, and uncomplicated skin and skin structure infections.
- Associated Conditions
- Acute Exacerbation of Chronic Bronchitis (AECB), Community Acquired Pneumonia (CAP), Lower Respiratory Tract Infection (LRTI), Pharyngitis, Secondary Infection, Skin and Soft Tissue Infections (SSTIs), Tonsillitis, Upper Respiratory Tract Infection
Semi-replicate Crossover Bioequivalence Study of Dirithromycin of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) in Healthy Subjects Under Fasting Conditions
- Conditions
- Healthy
- Interventions
- Drug: DYNABAC 250 MG ENTERIC COATED TABLET
- First Posted Date
- 2014-09-11
- Last Posted Date
- 2020-09-18
- Lead Sponsor
- Pharmaceutical Research Unit, Jordan
- Target Recruit Count
- 48
- Registration Number
- NCT02237768
- Locations
- 🇯🇴
Arab Pharmaceutical industry Consulting/ Pharmaceutical Research Unit, Amman, Jordan
Semi-replicate Crossover Bioequivalence Study of Dirithromycin in Healthy Subjects Under Fed Conditions
- Conditions
- Healthy
- Interventions
- Drug: DYNABAC 250 MG ENTERIC COATED TABLET
- First Posted Date
- 2014-09-11
- Last Posted Date
- 2020-09-18
- Lead Sponsor
- Pharmaceutical Research Unit, Jordan
- Target Recruit Count
- 48
- Registration Number
- NCT02237807
- Locations
- 🇯🇴
Arab Pharmaceutical industry Consulting/ Pharmaceutical Research Unit, Amman, Jordan
Bioequivalence Pilot Study of Dirithromycin of (Abdi İbrahim İlaç San.Ve.Tic.A.Ş,Turkey) in Healthy Subjects Under Fasting Condition
- Conditions
- Healthy
- Interventions
- Drug: DYNABAC 250 MG ENTERIC COATED TABLET
- First Posted Date
- 2014-07-10
- Last Posted Date
- 2014-07-10
- Lead Sponsor
- Pharmaceutical Research Unit, Jordan
- Target Recruit Count
- 12
- Registration Number
- NCT02185833
- Locations
- 🇯🇴
Arab Pharmaceutical industry Consulting/ Pharmaceutical Research Unit, Amman, Jordan
Bioequivalence Pilot Study of Dirithromycin of (Abdi İbrahim İlaç San.Ve.Tic.A.Ş,Turkey) in Healthy Subjects Under Fed Condition
- Conditions
- Healthy
- Interventions
- Drug: DYNABAC 250 MG ENTERIC COATED TABLET
- First Posted Date
- 2014-07-10
- Last Posted Date
- 2014-07-10
- Lead Sponsor
- Pharmaceutical Research Unit, Jordan
- Target Recruit Count
- 12
- Registration Number
- NCT02185846
- Locations
- 🇯🇴
Arab Pharmaceutical industry Consulting/ Pharmaceutical Research Unit, Amman, Jordan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.